NASDAQ:LVTX LAVA Therapeutics (LVTX) Stock Price, News & Analysis $1.42 -0.10 (-6.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 08/1/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LAVA Therapeutics Stock (NASDAQ:LVTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LAVA Therapeutics alerts:Sign Up Key Stats Today's Range$1.41▼$1.4850-Day Range$1.28▼$1.5252-Week Range$0.85▼$2.09Volume38,919 shsAverage Volume53,208 shsMarket Capitalization$37.36 millionP/E RatioN/ADividend YieldN/APrice Target$3.17Consensus RatingHold Company Overview LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. Read More LAVA Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreLVTX MarketRank™: LAVA Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 778th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingLAVA Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageLAVA Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about LAVA Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LAVA Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LAVA Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLAVA Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LAVA Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.40% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently decreased by 10.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLAVA Therapeutics does not currently pay a dividend.Dividend GrowthLAVA Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.40% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently decreased by 10.55%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for LVTX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of LAVA Therapeutics is held by insiders.Read more about LAVA Therapeutics' insider trading history. Receive LVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LVTX Stock News HeadlinesLAVA Therapeutics Shareholders Approve Key Proposals in MeetingJune 13, 2025 | tipranks.comHere's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn SituationMay 16, 2025 | finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 2 at 2:00 AM | Brownstone Research (Ad)LAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 15, 2025 | finanznachrichten.deLAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 14, 2025 | globenewswire.comLAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock NewsApril 16, 2025 | gurufocus.comLAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...April 16, 2025 | gurufocus.comLAVA Therapeutics Granted Full Waiver for RVO Payment ObligationApril 16, 2025 | globenewswire.comSee More Headlines LVTX Stock Analysis - Frequently Asked Questions How have LVTX shares performed this year? LAVA Therapeutics' stock was trading at $0.9510 at the start of the year. Since then, LVTX stock has increased by 49.3% and is now trading at $1.42. How were LAVA Therapeutics' earnings last quarter? LAVA Therapeutics N.V. (NASDAQ:LVTX) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.24. When did LAVA Therapeutics IPO? LAVA Therapeutics (LVTX) raised $100 million in an IPO on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of LAVA Therapeutics? Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LAVA Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), New Oriental Education & Technology Group (EDU), ServiceNow (NOW) and AppLovin (APP). Company Calendar Last Earnings5/14/2025Today8/02/2025Next Earnings (Estimated)8/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LVTX CIK1840748 Webwww.lavatherapeutics.com Phone31-85-016-3100FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for LAVA Therapeutics$3.17 High Price Target$6.00 Low Price Target$1.50 Potential Upside/Downside+123.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.11 million Net MarginsN/A Pretax Margin-545.07% Return on Equity-86.38% Return on Assets-34.12% Debt Debt-to-Equity RatioN/A Current Ratio6.73 Quick Ratio6.73 Sales & Book Value Annual Sales$11.98 million Price / Sales3.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book1.34Miscellaneous Outstanding Shares26,310,000Free Float23,806,000Market Cap$37.36 million OptionableOptionable Beta0.49 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:LVTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.